Molecular Partners hat die Wiederaufnahme des Bookbuilding-Verfahrens erfolgreich abgeschlossen und kotiert ihre Aktien an der SIX Swiss Exchange Dienstag, 04. November 2014 - 07:04
![]() | ||||||||||||||||||
This is a restricted communication and you must not forward it or its contents to any person to whom forwarding it is prohibited by the legends contained therein. In particular, this release and the information contained therein is not being issued and may not be distributed in the United States of America, Canada, Australia or Japan and does not constitute an offer of securities for sale in such or any other countries.
| ||||||||||||||||||
| Medienmitteilung (PDF) | ||||||||||||||||||
Molecular Partners hat die Wiederaufnahme des Bookbuilding-Verfahrens erfolgreich abgeschlossen und kotiert ihre Aktien an der SIX Swiss Exchange | ||||||||||||||||||
Zürich-Schlieren, 4. November, 2014. Molecular Partners AG hat das am 3. November wieder aufgenommene Bookbuilding-Verfahren für ihren Börsengang an der SIX Swiss Exchange erfolgreich abgeschlossen. Aufgrund der grossen Nachfrage von Schweizer und internationalen institutionellen sowie privaten Investoren hat die Gesellschaft den Zeitplan gekürzt und das Bookbuilding-Verfahren gestern Montag, um 17.00 Uhr MEZ, abgeschlossen.
Molecular Partners hat die 4'400'000 angebotenen Aktien mit einem Nennwert von jeweils CHF 0.10 erfolgreich bei institutionellen Investoren im In-und Ausland und bei Privatinvestoren in der Schweiz platziert. Der Angebotspreis von CHF 22.40 pro angebotener Aktie („Angebotspreis“) impliziert auf Basis der verwässerten Anzahl Aktien eine Marktkapitalisierung nach Neugeldzufluss von rund CHF 485 Mio. (post-money equity value, vor Ausübung der Mehrzuteilungsoption). Die Aktien (Tickersymbol: MOLN) werden voraussichtlich am Mittwoch, den 5. November 2014, erstmals an der SIX Swiss Exchange gehandelt.
Das gesamte Basisangebot („Basisangebot“) bestand aus 4'400'000 angebotenen Aktien („angebotene Aktien“), wobei 4'307'000 neu auszugebende Aktien von Molecular Partners angeboten und 93'000 bestehende Aktien im Auftrag einzelner Gründer und Mitglieder der Geschäftsleitung veräussert wurden, um im Zusammenhang mit dem Börsengang entstehende Steuerschulden zu decken.
Molecular Partners hat ausserdem den Konsortialbanken eine Mehrzuteilungsoption von bis zu 660'000 neu auszugebenden Aktien gewährt, die innerhalb von 30 Tagen nach dem ersten Handelstag an der SIX Swiss Exchange ausgeübt werden kann.
Die angebotenen Aktien entsprechen rund 22.8% des ausgegebenen Aktienkapitals nach Abschluss des Börsengangs (vor Ausübung der Mehrzuteilungsoption), respektive rund 25.4% unter vollständiger Ausübung der Mehrzuteilungsoption von bis zu 660'000 Aktien.
J.P. Morgan agiert als alleinige Konsortialführerin und Joint Bookrunner und die UBS Investmentbank als Joint Bookrunner. Co-Manager im Zusammenhang mit dem Börsengang sind Cowen and Company und die Bank am Bellevue.
Wichtige Informationen für die Medien
Provisorischer Zeitplan
| ||||||||||||||||||
Kontakt für Medienanfragen
Legal Notice
This announcement is not an offer to sell, or a solicitation of an offer to purchase, any securities of Molecular Partners AG (the “Company”), nor shall it or any part of it form the basis of, or be relied on in connection with any contract or investment decision. This announcement is not for publication or distribution (directly or indirectly) in or to the United States, Canada, Australia, Japan or any other jurisdiction in which such distribution would be unlawful.
This announcement is not an offer of securities for sale in the United States. The securities to which this announcement relates have not been and will not be registered under the United States Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act. There will not be a public offering of securities in the United States.
This announcement is not an offering circular within the meaning of Article 652a of the Swiss Code of Obligations, nor is it a listing prospectus within the meaning of the listing rules of the SIX Swiss Exchange or a prospectus under any other applicable laws. Investors should not subscribe for or purchase any securities referred to in this announcement except on the basis of information in any prospectus (and any supplement(s) thereto) which may be published in due course. This document does not constitute a recommendation regarding the shares. Copies of any prospectus are available free of charge from the Company’s registered office or from JP Morgan, c/o Equity Syndicate Desk, 25 Bank St., London E14 5JP, United Kingdom (telephone: +44 207 134 2592) and UBS AG, Prospectus Library, P.O. Box, 8098 Zurich, Switzerland (telephone: +41 44 239 47 03, facsimile: +41 44 239 69 14, email: swiss-prospectus@ubs.com).
This communication is directed only at persons (i) who are outside the United Kingdom or (ii) who have professional experience in matters relating to investments and who fall within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the "Order") or (iii) who fall within article 49(2)(a) to (d) ("high net worth companies, unincorporated associations etc.") of the Order (all such persons together being referred to as "Relevant Persons"). Any investment or investment activity to which this communication relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. Any person who is not a Relevant Person must not act or rely on this communication or any of its contents.
This communication does not constitute an "offer of securities to the public" within the meaning of Directive 2003/71/EC of the European Union (the "Prospectus Directive") of the securities referred to herein in any member state of the European Economic Area (the "EEA"). Any offers of the securities referred to in this announcement to persons in the EEA will be made pursuant to an exemption under the Prospectus Directive, as implemented in member states of the EEA, from the requirement to produce a prospectus for offers of the Securities.
This announcement contains statements that are, or may be deemed to be, forward-looking statements. In some case, these forward-looking statements can be identified by the use of forward-looking terminology or subjective assessments, including the words “potential”, “expects”, “targets”, “designed”, “intends” or “plans” or comparable terminology or by discussions of plans, objectives, targets, goals, future events or intentions. These forward-looking statements include matters that are not historical facts or which may not otherwise be provable by reference to past events, and are based on assumptions. By their nature, forward-looking statements are subject to known and unknown risks and uncertainties because they relate to events and/or depend on circumstances that may or may not occur in the future. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied by these statements and forecasts. Past performance of the Company cannot be relied on as a guide to future performance.
The information, opinions and forward-looking statements contained in this announcement speak only as at its date, and are subject to change without notice. Neither the Company nor any other person undertakes any obligation to review, update, confirm, or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this announcement.
Each of the Sole Global Coordinator, the Joint Bookrunners and Co-Managers is acting exclusively for the Company in connection with the planned offering. They will not regard any other person as their respective client in relation to the planned offering and will neither be responsible nor provide protection to anyone other than the Company, nor will they provide advice to anyone other than the Company in relation to the planned offering, the contents of this announcement or any other matter referred to herein.
In connection with the offer or sale of the securities referred to herein, the underwriters may over-allot the securities or effect transactions with a view to supporting the market price of the securities at a level higher than that which might otherwise prevail. Any stabilisation action or over-allotment will be conducted by the underwriters in accordance with all applicable laws and rules. Save as required by law or regulation, the underwriters do not intend to disclose the extent of any stabilisation action. No representation is made as to whether the underwriters will engage in any stabilisation activity or that this activity, if commenced, will not be discontinued without notice. |

